• English
    • العربية
  • العربية
  • Login
  • QU
  • QU Library
  •  Home
  • Communities & Collections
  • Help
    • Item Submission
    • Publisher policies
    • User guides
    • FAQs
  • About QSpace
    • Vision & Mission
View Item 
  •   Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Faculty Contributions
  • College of Arts & Sciences
  • Mathematics, Statistics & Physics
  • View Item
  • Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Faculty Contributions
  • College of Arts & Sciences
  • Mathematics, Statistics & Physics
  • View Item
  •      
  •  
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.

    Thumbnail
    View/Open
    s41467-022-30895-3.pdf (1.682Mb)
    Date
    2022-06-02
    Author
    Chemaitelly, Hiam
    Ayoub, Houssein H
    AlMukdad, Sawsan
    Coyle, Peter
    Tang, Patrick
    Yassine, Hadi M
    Al-Khatib, Hebah A
    Smatti, Maria K
    Hasan, Mohammad R
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar Hassan
    Latif, Ali Nizar
    Shaik, Riyazuddin Mohammad
    Abdul-Rahim, Hanan F
    Nasrallah, Gheyath K
    Al-Kuwari, Mohamed Ghaith
    Butt, Adeel A
    Al-Romaihi, Hamad Eid
    Al-Thani, Mohamed H
    Al-Khal, Abdullatif
    Bertollini, Roberto
    Abu-Raddad, Laith J
    ...show more authors ...show less authors
    Metadata
    Show full item record
    Abstract
    SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4-57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2-58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2-67.0%) and 43.7% (95% CI: 36.5-50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70-80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.
    DOI/handle
    http://dx.doi.org/10.1038/s41467-022-30895-3
    http://hdl.handle.net/10576/32084
    Collections
    • Biomedical Research Center Research [‎785‎ items ]
    • Biomedical Sciences [‎796‎ items ]
    • COVID-19 Research [‎848‎ items ]
    • Mathematics, Statistics & Physics [‎786‎ items ]
    • Public Health [‎480‎ items ]

    entitlement


    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU

     

     

    Home

    Submit your QU affiliated work

    Browse

    All of Digital Hub
      Communities & Collections Publication Date Author Title Subject Type Language Publisher
    This Collection
      Publication Date Author Title Subject Type Language Publisher

    My Account

    Login

    Statistics

    View Usage Statistics

    About QSpace

    Vision & Mission

    Help

    Item Submission Publisher policiesUser guides FAQs

    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU

     

     

    Video